More stories
Psychedelic Funding Update: Q2 2025
We have updated our Psychedelic Company Financing Tracker to reflect activity in Q2 2025. In 2025 we see a similar pattern to 2024, with...
Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI,...
In this expansive episode of Psychedelics Today, Joe Moore sits down with author and cultural theorist Daniel Pinchbeck to explore the evolving—and increasingly contested—role...
From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook
On Wednesday afternoon at Psychedelic Science I (Psychedelic Alpha Editor Josh Hardman) sat down with former U.S. Senator Kyrsten Sinema for a conversation about...
Oregon Psilocybin Services Tracker: Q1 2025
Q1 2025 Produced by Alice Lineham and Josh Hardman As the first cut of data from Oregon’s psilocybin program becomes available, we take a...
Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics
Chris Timmermann PhD is one of the UK’s leading researchers at the frontier of consciousness science. A Research Fellow in Neuroscience, Meditation and Psychedelics...
Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning
In this wide-ranging conversation, journalist Mattha Busby joins Joe Moore to reflect on the shifting tone of the psychedelic movement in the wake of...
Dylan Beynon – Mindbloom – At Home Ketamine
PT welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S. Dylan shares...
Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study
British psychedelic drug developer Beckley Psytech has shared topline data from a Phase 2b study of its lead candidate, intranasal 5-MeO-DMT (BPL-003), in treatment-resistant...
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans
Psychedelic Alpha’s Josh Hardman sat down with Beckley Psytech CEO Cosmo Feilding-Mellen and Chief Scientific and Medical Officer Rob Conley to discuss today’s topline...
Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model
This morning, executives from Beckley Psytech and atai Life Sciences hosted a conference call to discuss the topline results from their Phase 2b study...
Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout
This is the second of a two-part series that looks at how people are reacting to Compass Pathways’ first readout from its Phase 3...
It’s Time to Push Back: Meta’s War on Psychedelic Voices
META is doing real damage to the psychedelic ecosystem.Shadowbans. Post removals. Account suspensions. Entire orgs—especially nonprofits—shut out of digital visibility with no explanation and...
